Drugs / Uliledlimab
Uliledlimab
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03835949 | Jul 2019 → Jun 2022 | metastatic malignant neoplasm | Tracon Pharmaceuticals Inc. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04322006 | May 2020 → Apr 2025 | neoplasm | TJ Biopharma Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07005336 | Jan 2025 → Aug 2026 overdue | non-small cell lung carcinoma | TJ Biopharma Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05001347 | Nov 2021 → Feb 2023 | digestive system cancer, head and neck cancer, non-small cell lung carcinoma, ovarian carcinoma +1 | I-Mab Biopharma US Limited | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06984588 | Mar 2024 → Aug 2028 expected | non-small cell lung carcinoma | TJ Biopharma Co., Ltd. | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT04869501 Background | — | cancer | I-Mab Biopharma US Limited | No longer available | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Uliledlimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07005336 ↗ |
| Known as | TJ-D5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650519 ↗ |
| Known as | TJ004309 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03835949 ↗ |
| Modality | Monoclonal antibody | — CHEMBL4650519 ↗ |
| Route | Intravenous | “intravenous uliledlimab” NCT06984588 ↗ |